Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 6, 1996, Pages 608-618

  Gosse, Marilyn E ^a   DiMasi, Joseph A ^a   Nelson, Toben F ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DATA BASE; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DATABASES, FACTUAL; DRUGS, INVESTIGATIONAL; HUMANS; RECOMBINANT PROTEINS; UNITED STATES;

EID: 0030458024     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90209-X     Document Type: Short Survey

References (11)

1. BIO editors' and reporters' guide to biotechnology. Washington, DC: Biotechnology Industry Organization, 1995.
2. Bienz-Tadmor B, Brown J. Biopharmaceuticals and conventional drugs: comparing development times. BioPharm 1994;7:44-9.
3. Gosse ME, Manocchia M. First biologicals approved in the U.S.: 1980-1994. DIA Journal 1996 [in press].
4. Top 25 products in 1993. Scrip 1994;1962:27.
5. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992 [supplemented with information from Tufts Center for the Study of Drug Development Marketed NCE Database, 1963-1995]. Clin Pharmacol Ther 1994;55:609-22.
6. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994;55:609-22.
7. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58:1-14.
8. Bienz-Tadmor B, DiCerbo PA, Tadmor G, Lasagna L. Biopharmaceuticals and conventional drugs: clinical success rates. Biotechnology (NY) 1992;10:521-5.
9. Struck MM. Biopharmaceutical R&D success rates and development times: a new analysis provides benchmarks for the future. Biotechnology (NY) 1994;12:674-7.
10. Van Brunt J. The promise of gene therapy still lures big investors. BioWorld Financial Watch 1995;3:1-4.
11. Craig C. Genomics among hottest biotech investment areas. BioWorld Today 1996;7:1,5.